NMS·Healthcare·$1.4B·#263 / 520 in Healthcare
ZBIO Zenas BioPharma, Inc.
43SPECULATIVE
CATEGORY BREAKDOWN
GROWTH100
QUALITY0
STABILITY46
VALUATION0
GOVERNANCE61
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+100.0%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
8 months
19
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
0.5%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
135.0x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-2014
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
24.5%
92
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+49.1%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE ZBIO WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when ZBIO's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.